Who Owns Sartorius Stedim Biotech Company?

Sartorius Stedim Biotech Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Sartorius Stedim Biotech?

Understanding company ownership is key to grasping its strategy and accountability. Sartorius Stedim Biotech, a vital supplier to the biopharmaceutical sector, was formed in 2007 by merging Stedim S.A. and Sartorius AG's Biotechnology Division.

This union established a significant international partner for biopharmaceutical research and production, with its headquarters in Aubagne, France. The company is known for its single-use technologies and a broad product portfolio supporting the entire biopharmaceutical manufacturing process, including solutions like the Sartorius Stedim Biotech BCG Matrix.

As of December 31, 2024, Sartorius Stedim Biotech had 9,901 employees globally and reported sales revenue of 2,780 million euros for 2024. The company's market capitalization stood at $20.3 billion with 97.3 million shares outstanding as of July 29, 2025. This analysis will explore its ownership journey, from its inception to its current major shareholders, including the controlling interest held by Sartorius AG and the impact of public investors.

Sartorius Stedim Biotech was formed in 2007 from the merger of Stedim S.A. and Sartorius AG's Biotechnology Division. Stedim S.A. began in 1978, founded by Bernard Lemaître and Bernard Vallot with an initial focus on specialized bags for intravenous nutrient supply.

Founding of Stedim S.A.

Stedim S.A. was established in 1978 by Bernard Lemaître and Bernard Vallot in Aubagne, France. Their initial aim was to develop specialized ethylene vinyl acetate (EVA) bags for intravenous nutrient supply.

Early Commercial Focus

Within five years, Stedim shifted its commercial strategy, partnering with pharmaceutical companies like Pharmacia in 1984 and Baxter in 1986. These collaborations focused on the field of total parenteral nutrition.

Biotechnology Pivot

By the early 1990s, Stedim identified the growing potential in biotechnology. They began developing single-use bag systems, offering an alternative to traditional steel and glass containers for the biopharmaceutical industry.

Merger Formation

The company as it is known today, Sartorius Stedim Biotech, was established in 2007. This was achieved through the strategic merger of Stedim S.A. and the Biotechnology Division of Sartorius AG.

Early Ownership Details

Specific details regarding the initial equity splits or shareholdings of the founders at the inception of Stedim S.A. are not readily available in public records. Information on early investors or initial ownership agreements is also limited.

Lack of Early Dispute Information

Similarly, information concerning early agreements such as vesting schedules, buy-sell clauses, or any initial ownership disputes related to Stedim S.A. is not specified in the available information.

The evolution of Sartorius Stedim Biotech began with Stedim S.A., founded in 1978 by Bernard Lemaître and Bernard Vallot. Their initial focus was on creating specialized ethylene vinyl acetate (EVA) bags for patients requiring intravenous nutrient supply, particularly those with severely compromised digestive systems. This early specialization laid the groundwork for their future innovations in the biopharmaceutical sector.

Stedim's Strategic Evolution

Stedim S.A. strategically shifted its commercial focus approximately five years after its founding. This pivot involved collaborations with major pharmaceutical entities, including Pharmacia in 1984 and Baxter in 1986, concentrating on the area of total parenteral nutrition.

• Founding Year: 1978
• Founders: Bernard Lemaître and Bernard Vallot
• Initial Product Focus: Specialized EVA bags for intravenous nutrient supply
• Early Pharmaceutical Collaborations: Pharmacia (1984), Baxter (1986)

In the early 1990s, Stedim recognized the burgeoning potential within the biotechnology field. This foresight led to the development of innovative single-use bag systems designed for the biopharmaceutical industry. These systems offered a modern alternative to the traditional, more cumbersome steel and glass containers, marking a significant advancement in bioprocessing technology. Understanding the Target Market of Sartorius Stedim Biotech is crucial to appreciating this strategic shift.

Sartorius Stedim Biotech SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Sartorius Stedim Biotech has evolved significantly since its formation in 2007 through the integration of Sartorius AG's Biotechnology Division with Stedim S.A. This strategic move established a clear majority ownership by Sartorius AG, which has remained a dominant force in the company's shareholding structure.

As of February 7, 2024, Sartorius AG holds a substantial majority of Sartorius Stedim Biotech S.A.'s share capital, accounting for 71.5%, and controls 83.0% of the outstanding voting rights. The remaining 28.5% of shares are publicly traded, representing 17.0% of the voting rights, making Sartorius Stedim Biotech a publicly traded entity on the Euronext Paris stock exchange. This structure indicates that while Sartorius AG maintains significant control, a considerable portion of the company is accessible to public investors, influencing its market dynamics and strategic direction. The dilution of Sartorius AG's stake in the first half of 2024, from 73.6% to approximately 71.5% of share capital following a capital increase, highlights ongoing adjustments in the ownership landscape.

Key Stakeholders in Sartorius AG

Understanding the ownership of Sartorius Stedim Biotech also involves looking at its parent company, Sartorius AG. The Sartorius Trust is a major influence, managing a significant portion of the common shares and voting rights.

• Sartorius AG is headquartered in Göttingen, Germany, and is listed on the Frankfurt Stock Exchange.
• The Sartorius Trust manages approximately 50.1% of Sartorius AG's common shares and voting rights.
• Bio-Rad Laboratories Inc. holds around 38% of Sartorius AG's ordinary shares and approximately 28% of its preference shares.
• The remaining approximately 7% of Sartorius AG's ordinary shares are in free float.

Major institutional investors play a crucial role in the public float of Sartorius Stedim Biotech, contributing to its diverse shareholder base. These entities provide significant capital and influence market perception, aligning with the company's strategic objectives and its Mission, Vision & Core Values of Sartorius Stedim Biotech.

Prominent Institutional Investors

A number of large institutional investors hold stakes in Sartorius Stedim Biotech, reflecting confidence in its market position and growth prospects. These investors are key players in the public float, influencing trading volumes and stock performance.

• BlackRock, Inc.
• Comgest S.A.
• The Vanguard Group, Inc.
• T. Rowe Price Group, Inc.
• Baillie Gifford & Co.
• Invesco Ltd.
• TD Asset Management, Inc.
• Premier Fund Managers Ltd.
• State Street Global Advisors, Inc.

Sartorius Stedim Biotech PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of March 26, 2024, the Board of Directors for Sartorius Stedim Biotech S.A. includes Chairman Joachim Kreuzburg, CEO René Fáber, and members Pascale Boissel, Susan Dexter, Romaine Fernandes, Anne-Marie Graffin, Lothar Kappich, and Henri Riey. Anne-Marie Graffin holds the position of Lead Independent Director. A significant transition is planned for July 1, 2025, with Dr. Michael Grosse, who will succeed Joachim Kreuzburg as CEO of Sartorius AG, being co-opted onto the Board and appointed as Chairman, following Dr. Kreuzburg's resignation from the Board effective June 30, 2025.

The Board of Directors comprises eight members, with three designated as independent. Directors are typically appointed for a three-year term and, excluding the employee representative, are individually elected by the shareholders during Ordinary General Meetings. This structure ensures a degree of oversight and accountability to the broader shareholder base. Understanding the Marketing Strategy of Sartorius Stedim Biotech can provide context for the board's decisions.

Voting Power and Ownership Structure

Sartorius Stedim Biotech S.A. operates with a voting structure that includes shares with double voting rights. As of February 7, 2024, the company had a total of 165,581,058 voting rights. Sartorius AG holds a dominant position, controlling 83.0% of these voting rights, largely due to its significant shareholding and the company's dual-class share system. Further reinforcing this control, the Sartorius Trust manages approximately 50.1% of Sartorius AG's common shares and voting rights. The voting power held by the Sartorius Trust is exercised at the trustee's discretion, currently Dr. Lothar Kappich, until mid-2028.

• Sartorius AG holds 83.0% of voting rights as of February 7, 2024.
• The Sartorius Trust controls about 50.1% of Sartorius AG's common shares and voting rights.
• Voting rights from the Sartorius Trust are managed by a trustee until mid-2028.
• The company utilizes a dual-class share structure, impacting voting power.

Sartorius Stedim Biotech Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments have subtly shifted the ownership landscape of Sartorius Stedim Biotech. A significant capital increase in early 2024 led to a slight dilution of Sartorius AG's stake, while leadership transitions are set to occur in mid-2025.

The company's financial performance in 2024 demonstrated resilience, with sales revenue reaching 2,780 million euros, maintaining the prior-year level. This stability is supported by a robust equity ratio of 48.7% as of December 31, 2024. Looking ahead to 2025, management anticipates profitable, moderate growth, primarily fueled by its recurring consumables business. Strategic financial management includes continued organic debt reduction, with a focus on optimizing working capital and investment management.

Sartorius AG's Evolving Stake

Following a capital increase in February 2024, Sartorius AG's ownership in Sartorius Stedim Biotech S.A. saw a slight reduction. This adjustment moved its holding from 73.6% at the close of 2023 to approximately 71.5% by early February 2024.

Leadership Transition on the Horizon

A notable leadership change is scheduled for mid-2025. Dr. Joachim Kreuzburg will step down as Chairman of the Board of Sartorius Stedim Biotech on June 30, 2025, with Dr. Michael Grosse set to assume the role of Chairman effective July 1, 2025.

Financial Performance and Outlook

The company achieved sales revenue of 2,780 million euros in 2024, matching the previous year's performance. Management projects moderate, profitable growth for 2025, driven by the consumables segment.

Strategic Financial Management

Sartorius Stedim Biotech maintains a strong equity ratio of 48.7% as of December 31, 2024. The company plans to continue its organic debt reduction strategy, focusing on working capital efficiency and investment oversight, building on its Brief History of Sartorius Stedim Biotech.

Sartorius Stedim Biotech Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔